Research makes strong case for broader use of GLP1 drugs to protect hearts

https://www.news-medical.net/news/20260928/Research-makes-strong-case-for-broader-use-of-GLP1-drugs-to-protect-hearts.aspx New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) makes a case for extending the indication for GLP1- receptor agonists (GLP1-RAs) to millions more people, to protect their heart health. The GLP1-RA drugs semaglutide and tirzepatide are approved for weight loss in adults with a BMI of ≥30 or a BMI of ≥27 plus at least one weight-related health condition e.g. dyslipidaemia (unhealthy levels of cholesterol or other fats in the blood), high blood pressure, type 2 diabetes or previous cardiovascular disease.